Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Harpoon Therapeutics Inc
(NQ:
HARP
)
23.01
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Harpoon Therapeutics Inc
< Previous
1
2
Next >
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
April 17, 2023
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and...
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
April 10, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 27, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
March 27, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
March 14, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 07, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
MarketBeat: Week in Review 12/12 - 12/16
December 17, 2022
A triple-witching day means it could be a rough end to a trading week. Before you step away for the holidays, here are some of the top articles from this week.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
Three Small-Cap Biotech Stocks to Consider Now
December 12, 2022
This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023
Via
MarketBeat
Harpoon Therapeutics (NASDAQ: HARP) Releases Updated Phase 1 Interim Results for HPN217 in Treating Relapsed Multiple Myeloma
December 12, 2022
Harpoon Therapeutics, Inc. (NASDAQ: HARP) is engaged as a clinical-stage immune-oncology company, which is focused on the research and development
Via
Spotlight Growth
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
December 11, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
December 05, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
November 03, 2022
Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022,...
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
October 04, 2022
Harpoon adds experienced drug developer to leadership team
From
Harpoon Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.